Rhopressa
Total Payments
$6.1M
Transactions
25,278
Doctors
9,286
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $437,963 | 322 | 191 |
| 2023 | $152,183 | 322 | 201 |
| 2019 | $3.3M | 14,360 | 6,426 |
| 2018 | $2.2M | 10,274 | 5,458 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.0M | 179 | 33.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.9M | 666 | 31.6% |
| Food and Beverage | $1.0M | 22,868 | 17.1% |
| Consulting Fee | $634,842 | 275 | 10.5% |
| Travel and Lodging | $414,408 | 1,279 | 6.8% |
| Grant | $13,354 | 11 | 0.2% |
Payments by Type
General
$4.0M
25,099 transactions
Research
$2.0M
179 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A MULTICENTER, OPEN-LABEL STUDY OF RHOPRESSA (NETARSUDIL OPHTHALMIC SOLUTION) 0.02% FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION IN A REAL-WORLD SETTING | Aerie Pharmaceuticals, Inc. | $793,281 | 0 |
| A Prospective, Double-masked, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Assessing the Safety and Ocular Hypotensive Efficacy and Optimum Concentration to be used Clinically Of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular Hypertension in the United States | Aerie Pharmaceuticals, Inc. | $347,491 | 0 |
| A prospective, double-masked, randomized, multicenter, placebo controlled, parallel-group study assessing the safety of two concentrations of netarsudil ophthalmic solution in healthy Japanese/Japanese American volunteers in the United States | Aerie Pharmaceuticals, Inc. | $289,851 | 0 |
| A Randomized, Single Center, Masked, Crossover Study Comparing the Effects of Rhopressa (Netarsudil Ophthalmic Solution) and Timolol on Intraocular Pressure and Retinal Blood Vessel Density in Patients with Ocular Hypertension or Primary Open Angle Glaucoma | Aerie Pharmaceuticals, Inc. | $209,227 | 0 |
| Mechanism of Action and Efficacy of Fixed Combination Latanoprost + Netarsudil in Cell Culture and Potential Disease Modifying Effect | Alcon Research LLC | $142,016 | 0 |
| Prospective, Randomized Study to Evaluate the Effect of Rhopressa on Intraocular Pressure (IOP) in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension Post-Selective Laser Trabeculoplasty (SLT) | Alcon Research LLC | $95,829 | 0 |
| RANDOMIZED, DOUBLE- MASKED, PLACEBO-CONTROLLED EVALUATION OF NETARSUDIL FOR PREVENTION OF CORTICOSTEROID-INDUCED INTRAOCULAR PRESSURE ELEVATION | Aerie Pharmaceuticals, Inc. | $43,320 | 0 |
| The Possible Effect of Netarsudil on Transforming Growth Factor 2beta Signaling in Trabecular Meshwork Endothelial Cell Culture: a Potential Disease Modifying Effect. | Alcon Research LLC | $43,250 | 0 |
| Prospective randomized study to determine whether use of Rhopressa accelerates corneal clearing after removal of Descemet membrane for treatment of Fuchs dystrophy | Aerie Pharmaceuticals, Inc. | $20,600 | 0 |
| Measuring the Effects of Rhopressa on Episcleral and Retinal Blood Flow in Ocular Hypertension and Glaucoma Suspects using in vivo Erythrocyte Mediated Angiography | Alcon Research LLC | $15,722 | 0 |
| Prospective randomized study to determine whether use of Rhopressa can ammeliorate corneal edema associated with Fuchs dystrophy | Aerie Pharmaceuticals, Inc. | $12,445 | 0 |
| A Double-Masked Randomized, Placebo Controlled Study of Trabecular Outflow Facility Following Treatment With Netarsudil Ophthalmic Solution 0.02% (AR-13324) in Subjects With Elevated intraocular Pressure | Aerie Pharmaceuticals, Inc. | $11,330 | 0 |
Top Doctors Receiving Payments for Rhopressa
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Orange, CA | $2.1M | 193 |
| , MD | Ophthalmology | Dayton, OH | $155,545 | 158 |
| , M.D | Ophthalmology | Slingerlands, NY | $89,466 | 98 |
| , MD | Ophthalmology | Petaluma, CA | $89,254 | 117 |
| , M.D | Ophthalmology | La Jolla, CA | $86,320 | 104 |
| Ronald Gross | — | Morgantown, WV | $86,199 | 92 |
| , M.D | Glaucoma Specialist | Huntingdon Valley, PA | $83,915 | 74 |
| , MD | Ophthalmology | San Francisco, CA | $76,247 | 66 |
| , M.D | Ophthalmology | Ypsilanti, MI | $72,960 | 122 |
| , M.D | Ophthalmology | New York, NY | $67,527 | 89 |
| , MD | Ophthalmology | Syracuse, NY | $66,791 | 81 |
| , M.D | Ophthalmology | Bala Cynwyd, PA | $63,819 | 77 |
| , MD | Ophthalmology | Atlanta, GA | $55,217 | 70 |
| , M.D | Ophthalmology | New York, NY | $50,350 | 32 |
| , M.D | Ophthalmology | Wheaton, IL | $46,554 | 60 |
| , MD | Ophthalmology | Jupiter, FL | $45,460 | 57 |
| , M.D | Ophthalmology | Dallas, TX | $45,350 | 49 |
| , MD | Ophthalmology | Norfolk, VA | $43,315 | 46 |
| , MD | Ophthalmology | Venice, FL | $42,422 | 56 |
| , MD | Ophthalmology | Charlotte, NC | $41,359 | 68 |
| , M.D | Ophthalmology | Dallas, TX | $40,973 | 52 |
| , M.D | Ophthalmology | New York, NY | $40,372 | 36 |
| , M.D | Ophthalmology | Bethpage, NY | $35,589 | 31 |
| , MD | Ophthalmology | Memphis, TN | $34,820 | 48 |
| , MD | Ophthalmology | San Francisco, CA | $34,173 | 60 |
Ad
Manufacturing Companies
- Aerie Pharmaceuticals, Inc. $5.5M
- Alcon Research LLC $298,917
- Alcon Vision LLC $291,229
Product Information
- Type Drug
- Total Payments $6.1M
- Total Doctors 9,286
- Transactions 25,278
About Rhopressa
Rhopressa is a drug associated with $6.1M in payments to 9,286 healthcare providers, recorded across 25,278 transactions in the CMS Open Payments database. The primary manufacturer is Aerie Pharmaceuticals, Inc..
Payment data is available from 2018 to 2024. In 2024, $437,963 was paid across 322 transactions to 191 doctors.
The most common payment nature for Rhopressa is "Unspecified" ($2.0M, 33.7% of total).
Rhopressa is associated with 12 research studies, including "A MULTICENTER, OPEN-LABEL STUDY OF RHOPRESSA (NETARSUDIL OPHTHALMIC SOLUTION) 0.02% FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION IN A REAL-WORLD SETTING" ($793,281).